HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Regional molecular genetics centers in thoracic oncology: what and who should be tested?

Abstract : Management of NSCLC patients is more and more individualized especially on the base of bioguided treatments. In order to guarantee an access for all the patients too this type of strategy, the French NCI supports since 2006 a nationwide network of 28 regional genetics center. The financial support is based on public funds. The French NCI recommends today the assessment of seven biomarkers for all stage IV non squamous NSCLC patients. Due to financial and technical reasons, this recommendation must be followed. However, the molecular profiling of lung cancer patients would ideally be extended across all stages and all histological types of the disease in order to improve our knowledge in this field and provides the patient with an opportunity to access a bioguided treatment as frequently as possible.
Document type :
Journal articles
Complete list of metadata

Contributor : l'Houcine Ouafik Connect in order to contact the contributor
Submitted on : Tuesday, February 13, 2018 - 12:22:46 PM
Last modification on : Thursday, October 21, 2021 - 4:00:59 AM


  • HAL Id : hal-01708071, version 1



Fabrice Barlési, Pascale Tomasini, Frédéric Fina, Véronique Secq, Laurent Greillier, et al.. Regional molecular genetics centers in thoracic oncology: what and who should be tested?. Bulletin du Cancer, John Libbey Eurotext, 2013, 100 (7-8), pp.737-741. ⟨hal-01708071⟩



Record views